SUNNYVALE, Calif., Feb. 25, 2020 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Mercy Hospital St. Louis continues to demonstrate its commitment to improving patient outcomes with the installation of the first CyberKnife® M6™ System in Missouri at their state-of-the-art David C. Pratt Cancer Center. The next-generation CyberKnife System has been shown to deliver precise stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) treatments with ease, making it possible for the clinical team to expand access to one of the most advanced methods for administering radiation to more cancer patients.
SRS and SBRT are non-invasive forms of radiation therapy that use high doses of very targeted radiation to destroy tumors, in just a few treatment sessions (1 to 5). SRS is commonly used to treat conditions within the brain and spine, while SBRT is used for those tumors located outside these areas. The CyberKnife M6 System is equipped with sophisticated functionality that will streamline the creation of personalized treatment plans and reduce the time to deliver radiation treatments, enabling the Mercy St. Louis team to offer precision SRS and SBRT treatments to more patients each day.
The Mercy Hospital St. Louis team uses the most advanced radiotherapy technology to design and deliver an individualized treatment plan designed to help cancer patients take control of their disease and resume their lives. The hospital is part of the Mercy system, named one of the top five large U.S. health systems from 2016 to 2019 by IBM Watson Health. Mercy announced in 2018 that it intended to work with Accuray to enhance cancer care through advanced life-saving technology, including the CyberKnife System that was recently installed as well as Accuray Radixact® Systems that will be installed at other Mercy hospitals.
"The CyberKnife M6 is really an ideal system for the hospital and for our patients. The system combines sub-millimeter accuracy with real-time image guidance, enabling our team to effectively treat almost any part of the body requiring radiation therapy," said Robert Frazier, M.D., radiation oncologist and division chief for radiation oncology at Mercy Hospital St. Louis. "For example, when we treat patients with brain tumors, we will now be able to deliver a very high dose of radiation to the tumor, to eradicate the disease, while minimizing the dose to critical brain structures. Prostate cancer patients who would have been treated with daily radiation equal to 40-45 fractions over 8-9 weeks, can now be treated in just 5 fractions with the CyberKnife System. And, because CyberKnife prostate SBRT typically is associated with few side effects, these patients can return to their normal activity on the same day."
"We congratulate the Mercy Hospital St. Louis team on the installation of their CyberKnife M6 System. We are committed to supporting them in their goal to expand access to advanced radiotherapy. This most recent installation of the CyberKnife M6 System further demonstrates clinicians' confidence in the value the system will bring to their patients, their team and their hospital," said Joshua H. Levine, president and CEO at Accuray.
Important Safety Information
For Important Safety Information please refer to https://www.accuray.com/safety-statement.
About the CyberKnife System
The CyberKnife System is the only robotic radiosurgery system that offers highly precise, non-surgical treatment for tumors and lesions anywhere in the body—including the brain, breast, kidney, liver, lung, pancreas, prostate and spine. The CyberKnife System tracks and automatically adjusts for tumor or patient movement during treatment, delivering the radiation dose directly to the target with sub-millimeter precision. Synchrony® motion tracking and correction technology expands on the CyberKnife System's unique motion synchronization capabilities to provide additional precision when treating tumors that move with respiration. The high level of accuracy in dose delivery made possible by the system gives clinical teams the confidence to deliver state-of-the-art treatments for a wide range of cancers and functional disorders, without sacrificing patients' quality of life.
Accuray Incorporated (Nasdaq: ARAY) develops, manufactures and sells radiotherapy systems that are intended to make cancer treatments shorter, safer, personalized and more effective, ultimately enabling patients to live longer, better lives. Our radiation treatment delivery systems in combination with fully-integrated software solutions set the industry standard for precision and cover the full range of radiation therapy and radiosurgery procedures. For more information, please visit www.accuray.com or follow us on Facebook, LinkedIn, Twitter and YouTube.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to the anticipated installation of Radixact Systems at other Mercy hospitals, clinical applications, clinical results, patient experiences, patient outcomes and the company's ability to continue to penetrate the global radiation therapy market. These forward-looking statements involve risks and uncertainties. If any of these risks or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the company's ability to achieve widespread market acceptance of its products; the company's ability to develop new products or improve existing products to meet customers' needs; the company's ability to anticipate or keep pace with changes in the marketplace and the direction of technological innovation and customer demands and such other risks identified under the heading "Risk Factors" in the company's quarterly report on Form 10-Q, filed with the Securities and Exchange Commission (the "SEC") on February 4, 2020, and as updated periodically with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
Public Relations Director, Accuray
+1 (408) 789-4426
+1 (781) 684-6610
View original content to download multimedia:http://www.prnewswire.com/news-releases/first-accuray-cyberknife-m6-system-installed-in-missouri-at-mercy-hospital-st-louis-301010448.html
SOURCE Accuray Incorporated